JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:1498-1502, doi:10.1016/j.jacc.2006.09.004 (Published online 18 September 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Correction
Right arrow Correction (v48,p2610)
Right arrow All Versions of this Article:
j.jacc.2006.09.004v1
48/7/1498    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, M. M.
Right arrow Articles by Krumholz, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, M. M.
Right arrow Articles by Krumholz, H. M.

AHA/ACC SCIENCE ADVISORY

Influenza Vaccination as Secondary Prevention for Cardiovascular Disease

A Science Advisory From the American Heart Association/American College of Cardiology

Matthew M. Davis, MD, MAPP, Kathryn Taubert, PhD, FAHA, Andrea L. Benin, MD, David W. Brown, MSPH, MSc, George A. Mensah, MD, FAHA, FACC, Larry M. Baddour, MD, Sandra Dunbar, RN, DSN, FAHA and Harlan M. Krumholz, MD, FAHA, FACC

ABSTRACT: Evidence from cohort studies and a randomized clinical trial indicates that annual vaccination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in patients with cardiovascular conditions. The American Heart Association and American College of Cardiology recommend influenza immunization with inactivated vaccine (administered intramuscularly) as part of comprehensive secondary prevention in persons with coronary and other atherosclerotic vascular disease (Class I, Level B). Immunization with live, attenuated vaccine (administered intranasally) is contraindicated for persons with cardiovascular conditions. It is important to note that influenza vaccination coverage levels overall and in this population remain well below national goals and are marked by disparities across different age and ethnic groups. One of the barriers to vaccination for patients with cardiovascular disease is that cardiology practices frequently do not stock and administer influenza vaccine. Healthcare providers who treat individuals with cardiovascular disease can help improve influenza vaccination coverage rates by providing and strongly recommending vaccination to their patients before and throughout the influenza season.

Key Words: AHA Scientific Statements • cardiovascular diseases • influenza, human • influenza vaccines




This article has been cited by other articles:


Home page
 Eur Respir JHome page
A. G. S. C. Jansen, E. A. M. Sanders, A. W. Hoes, A. M. van Loon, and E. Hak
Influenza- and respiratory syncytial virus-associated mortality and hospitalisations
Eur. Respir. J., December 1, 2007; 30(6): 1158 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Offer Flu Vaccine in Your Cardiology Practice
Journal Watch Cardiology, October 11, 2006; 2006(1011): 1 - 1.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.